Biospecimen Banks to Support NCI National Clinical Trials Network (NCTN), NCI Community Oncology Research Program (NCORP) and CTEP-Supported Early Trials/Studies

Re-issue RFA/Cooperative Agreement/Limited Competition

Irina A. Lubensky, MD
Chief, Pathology Investigations & Resources Branch
Cancer Diagnosis Program, DCTD

BSA Meeting
June 10, 2019
Biospecimen Banks to Support NCI Clinical Trials

**Goal:** to collect, process, store and distribute well-annotated NCI Clinical Trials biospecimens for research

  - Grant PIs: pathologists specialized in biospecimen banking

- Specimens collected for NCTN phase III, phase II and other trials (on protocols) are well-annotated with clinical and outcome data

- Specimens initially used by NCTN trial Group Investigators for *integral* and *integrated biomarker* studies/assays (prognosis/prediction)

- Specimens remaining in excess after clinical trial requirements have been met become “legacy” specimens and are available to investigators for *secondary correlative studies* following a defined NCTN biospecimen access process and approval by NCTN Core Correlative Science Committee (NCTN CCSC)

## ALL Organ Sites; Adult & Pediatric Cancer

<table>
<thead>
<tr>
<th>Sample Type</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Samples*</td>
<td>440,114</td>
</tr>
<tr>
<td>- Solid Tumor Samples</td>
<td>410,248</td>
</tr>
<tr>
<td>- Leukemia Samples</td>
<td>29,866</td>
</tr>
</tbody>
</table>

## NCTN Investigators Served (Integral/integrated)

<table>
<thead>
<tr>
<th>Investigator Type</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCTN Investigators Served</td>
<td>223</td>
</tr>
</tbody>
</table>

## ALL Investigators Served (Legacy Specimens)

<table>
<thead>
<tr>
<th>Investigator Type</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCTN Group Investigators</td>
<td>220</td>
</tr>
<tr>
<td>Non-Group Investigators</td>
<td>128</td>
</tr>
</tbody>
</table>

## Publications

- **Publications** (based on specimens used for research) | 572

---

*Sample* is defined as one processed piece of a biospecimen, regardless of the sample size or type of initial processing: FFPE block/frozen tissue/vial/aliquot.
### Solid Tumors DISTRIBUTED by NCTN Banks (2013-2017)

<table>
<thead>
<tr>
<th>5 NCTN Groups</th>
<th>Samples</th>
<th>FFPE</th>
<th>Frozen</th>
<th>Plasma</th>
<th>Serum</th>
<th># of Trials OVER ENTIRE 2013 – 2017 PERIOD</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>106,902</td>
<td>41,025</td>
<td>2,042</td>
<td>27,235</td>
<td>18,682</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>74,163</td>
<td>24,990</td>
<td>1,526</td>
<td>22,155</td>
<td>14,342</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>50,615</td>
<td>34,018</td>
<td>4,404</td>
<td>5,270</td>
<td>7,411</td>
<td>316</td>
</tr>
<tr>
<td>2016</td>
<td>78,353</td>
<td>50,746</td>
<td>11,174</td>
<td>2,564</td>
<td>3,103</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>100,215</td>
<td>70,947</td>
<td>9,543</td>
<td>5,831</td>
<td>5,191</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>410,248</td>
<td>221,726</td>
<td>28,689</td>
<td>63,055</td>
<td>48,729</td>
<td></td>
</tr>
</tbody>
</table>

### Leukemia Specimens DISTRIBUTED by NCTN Banks (2013-2017)

<table>
<thead>
<tr>
<th>4 NCTN Groups</th>
<th>Samples</th>
<th>Bone Marrow</th>
<th>Blood WBC</th>
<th>DNA</th>
<th>RNA</th>
<th># of Trials OVER ENTIRE 2013 – 2017 PERIOD</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>6,823</td>
<td>2,251</td>
<td>265</td>
<td>1,393</td>
<td>1,233</td>
<td></td>
</tr>
<tr>
<td>2014</td>
<td>7,410</td>
<td>2,863</td>
<td>794</td>
<td>996</td>
<td>1,100</td>
<td></td>
</tr>
<tr>
<td>2015</td>
<td>6,373</td>
<td>3,614</td>
<td>284</td>
<td>1,037</td>
<td>714</td>
<td>83</td>
</tr>
<tr>
<td>2016</td>
<td>4,924</td>
<td>1,279</td>
<td>401</td>
<td>988</td>
<td>558</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>4,336</td>
<td>1,475</td>
<td>612</td>
<td>527</td>
<td>341</td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td>29,866</td>
<td>11,482</td>
<td>2356</td>
<td>4,941</td>
<td>3,946</td>
<td></td>
</tr>
</tbody>
</table>

"# of Trials Over Entire 2013-2017 Period" - number of unique trials involved across all 5 years, as number of trials with active sample distributions will vary from year to year.
NCTN Navigator | A Clinical Trials Specimen Resource

NCI’s National Clinical Trials Network (NCTN) Navigator is a resource for investigators who have typically conducted exploratory correlative analysis and are now seeking specimens to validate their hypotheses. Click the "Explore Specimens" button to the right to explore the inventory.

CTEP-IAM Log-In should only be used when you are ready to submit a LOI. If you have questions, please review the FAQs and if your question is not answered there, contact the Front Door Service for assistance.

Navigator Process Flow

The Navigator inventory is currently limited to select adult treatment trials that were conducted by NCI’s NCTN clinical trials Groups, Phase 3 or large biospecimen collection protocols with clinical data, and completed, with the primary outcome reported. For additional information on the process workflow, refer to the Steps for Researchers document.

1. Consolidate inventory of biospecimens
2. Connect biospecimens and clinical data
3. Provide biospecimen access to research community
4. Track applications
Published Data Load Status as of May 29, 2019

NCTN Navigator Specimens by Disease Category

- Gynecologic: 31%
- Breast: 30%
- GI: 11%
- Prostate/GU: 12%
- Lung: 7%
- Head & Neck: 3%
- Hematologic: 3%
- Other: 1%
- Brain: 2%
- Other: 1%

119 Trials
72,363 Patients
852,946 Specimens
Biospecimen Banks: U24-Cooperative Agreement (2020-2026)

Current funding:
5 NCTN banks (11.1 M/year) and ETCTN bank pilot (650K/year)

5 Awards for NCTN Biospecimen Banks $15.2M
- Infrastructure and operations
- NCTN Biospecimen IT Navigator & Front Door Service curation
- “Legacy” specimens retrieval, processing, QA/QC
- Specimens for CIMAC (specialized processing/handling)
- Specialized kits and tubes for collection sites & processing
- Digital whole slide images storage/scanning
- NCORP cancer prevention trials biospecimens (restricted) $1.8M
* New PEP-CTN Biospecimen Banking in COG NCTN Bank $0.23M

1 Award for Early Clinical Trials Bank (ETCTN, CITN, & CIMAC) $2.5M

Total cost for 6 Banks per year $19.73M
BSA Subcommittee Reviewers' Question

➢ To further understand the Navigator program, which is only in its first year, what are the demand metrics?

**Navigator: Investigator Requests as of May 29, 2019**

- 61 Letters of Intents (LOIs) submitted
  - 45 feasible (specific specimens & associated data are available)
  - 15 not feasible (specific specimens are not available)
  - 1 in review

Of the 45 feasible LOIs, 28 full proposals have been submitted
  - 6 approved
  - 2 pending
  - 8 disapproved
  - 12 scheduled for review in coming months
  - 17 not yet submitted by investigators to CCSC
BSA Subcommittee Reviewers' Question

➢ Is the data ever linked back to the original specimen? If yes, indicate if the data are easily available to other researchers and how one can access the data.

- NIH policies include requirements for data sharing and public access to publications from NCTN clinical trials
- De-identified patient-level data from all NCTN phase III and phase II/II trials must now be submitted to the NCTN/NCORP Data Archive (https://nctn-data-archive.nci.nih.gov/) after publication of the trial’s primary results (which may also include results from any integral biomarker included in the trial)
- Data submission to the Archive includes the dataset, data dictionary, and relevant metadata, along with a de-identified code for each patient that can be used for future linkage to genomic, imaging, or other specimen data contained in other databases
- For example, research proposals for use of “legacy” specimens from NCTN Navigator approved by the NCTN-CCSC may be submitted to NIH’s dbGAP/NCI Genomic Data Commons (https://gdc.cancer.gov/). If the trial data also exists in the NCTN/NCORP Data Archive, linked patient IDs can be provided to approved investigators to facilitate linkage between the patients’ specimens data and their trial data.
BSA Subcommittee Reviewers' Question

Has consideration been given to developing standards and common data elements to support and address the scalability of data?

- Each NCTN trial/study protocol is different and includes 100s or 1000s of data elements.
- NCTN uses the CDEs listed in the CDE Browser to facilitate cross study comparisons. There is a set of NCI Standard Modules and CDEs in the caDSR that have been vetted across the larger user community.
- There are ~1800 released NCI Standard CDEs on the list (another ~1000 are in draft status).

**CDE Browser:**
https://cdebrowser.nci.nih.gov/cdebrowserClient/cdeBrowser.html#/search

**NCI CDE Project:**
https://wiki.nci.nih.gov/display/cadsr/ctep+common+data+elements#CTEPCommonDataElements-StandardsLeveragedbytheCDEProject